U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN
The Dermatology Digest
FEBRUARY 18, 2025
It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. Every treatment approval is hard-won, built on research, persistence, and partnership.
Let's personalize your content